Drugs / IOV 3001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06940739 | Mar 2025 → Jun 2032 expected | metastatic melanoma, ocular melanoma | Iovance Biotherapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IOV 3001 | “A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will...” NCT06940739 ↗ |
| Modality | Protein / enzyme biologic | “IOV-3001 is an antibody interleukin-2 (IL-2) fusion protein” NCT06940739 ↗ |
| Route | Intravenous | “administered as a single dose by IV infusion” NCT06940739 ↗ |